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INTRODUCTION
Throughout the course of its existence, the Food and Drug Administration (FDA) has
been a somewhat overlooked entity. That is, until the FDA proclaims that something on
the American market available to consumers or doctors is unsafe or dangerous. The FDA
is responsible for regulating almost all foods consumed by humans, domestic animals,
and livestock. 1 In addition, the FDA regulates drugs, medical devices, biologics,
cosmetics, and radiation-emitting devices. In 2015, the FDA issued an average of 12.5
press releases each month. 2 In contrast, the U.S. Department of Health and Human
Services, which has similar goals of American consumer health and protection, issues
an average of 7.5 press releases each month. 3
Press releases containing adverse publicity, e.g., that products or classes of products
carry even the possibility of harm to the public, can be extremely harmful to the
products' manufacturers occasionally compelling the manufacturers to voluntarily
withdrawing the product. 4 Traditionally, the FDA has enforced its statutory mandate
by halting production or seizing tainted items before they reach the consumer market. 5
However, the FDA may be increasing its impact by relying more on press releases that
warn the public that products might carry some harm, whether it is proven or unproven. 6
And in today's world of breaking news stories getting through to the general public
through social media platforms like Twitter (which limits each post to 140 characters or
less), FDA press releases on the internet can create more misinformation and panic for
consumers and manufactures alike with every re-tweet.7
In addition, the FDA may use negative press releases as a threat, to effectively pressure
manufacturers to comply with regulations or voluntarily recall products. Manufacturers
may decide to incur the costs of voluntary compliance, instead of seeing their brands
harmed. In 1959, the FDA broadly announced that cranberries harvested in Washington
State and Oregon might be hazardous, because they had been treated with pesticides
that caused cancer in laboratory rats. 8 While the FDA warning may have had some
1
21 U.S.C. §§ 332, 334, 375 (2014) (outlining the FDA's role); but see§§
and 457(c)
l""""'"""''"the U.S. Food
and Inspection Service (FSIS) to regulate the U.S. commercial
of meat, poultry, and egg ""''"U<"'ec' 1

2

Press Announcements, FDA,
PressAnnouncements/2015/defaulthtm.
4

Ernest Gellorn, Adverse ,,11,nw·1111
that the FDA has made inaccurate statements that have
entities).
Id.
6

Id.

7

Michael Barthel et al., The
CENTER
16, 2015),
twitter-and-facebook/ (explaining that social media users across demographics increasingly use
social media
as their main source of news, --,·--·-··, news events as the events are
""f·'f.'"rn"'" which can lead to misinformation).
8

Lisa M. Willis, Third-Year Paper, No cnmo•en·zes
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positive effect, it failed to mention that only 1 percent of the cranberries grown in that
region were contaminated. 9 As a result, many perfectly good cranberries went unsold
and producers were unduly harmed. 10 This example demonstrates the significant impact
of one public statement from the FDA. 11
In the hyper-connected modem age, an FDA press release can impact manufacturers
and consumers in a matter of minutes. In recent years, the FDA, recognizing that press
releases are influential and cost-effective, has used them more and more often to regulate
products, particularly medical devices. 12 Overall, the numbers of FDA injunctions and
seizures have increased proportionally with the amount of recall events within the press
releases. However, these numbers are steadily increasing each year. 13 Unfortunately,
thus far, the FDA's press releases have not been wholly accurate. 14 Quite often, the
press releases contain alleged violations, which the internet can inflate, misreport, and
spread incredibly fast. The FDA has failed to use their power of publicity in a way that
best guides consumers and manufacturers alike. In order to better this unfortunate use
of power, the FDA must recognize that when adverse publicity is made available to the
public, the effects of such publicity go beyond the product or good at issue. Once that is
recognized, the solution is another obstacle the agency must face in the modem internet
age of irrevocable statements. Through an in-depth look at the handling of one medical
device, the issues of the FDA's use of publicity will be assessed, possible solutions to
the overall problem observed. Such solutions will then be addressed, hypothetically, to
the problem at issue in order to demonstrate how the FDA could potentially reign in its
abuse of publicity in such a fashion that would benefit all parties.

I. THE PROBLEM
Publicity has many benefits because it can quickly alert consumers ofhazardous products.
However, adverse publicity can cause undue harm on the manufacturers, that may
outweigh the benefit to consumers. Adverse publicity may be viewed as the deprivation
of a private person or firm's right to engage in commerce and free enterprise, without
the due process of law normally associated with government action. 15 In other words,
if the government makes a negative statement about a private actor or its product, the
private actor has no recourse, even if the statement is false. 16 The private actor can only

9

Id. at 6.

10

Id.

ll

21US.C.§375 (2014).

12

FDA
Statistics
Fiscal Year 2012, FDA (2013),
downloads/I CEClJEnfrircementActions/UCM346964.
13 Id
14

See
that the FDA
of all fruits grown in Chile, after
that grapes grmvn in Chile had been
and
grapes in the US. market).

vrn,rnn,,u

and the FDA, An

16

Id
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hope the government uses common sense and does not abuse its discretion. 17 Moreover,
judicial review and potential monetary compensation for market losses cannot undo the
widespread effects of erroneous adverse publicity because, with sovereign immunity,
such judicial review is unavailable to those injured. 18 A negative FDA press release
can have lasting harm to a particular product's marketing or to a manufacturer's overall
reputation, even if the press release is later proved to be true only in part. 19 For example,
in the mid-1990s, the U.S. Embassy in Chile received two anonymous tips that grapes
grown in Chile and shipped to the United States had been contaminated with cyanide. 20
The FDA then found puncture marks in two Chilean grapes, quickly concluded the
anonymous tips must be true, and banned all Chilean fruits from entering the United
States. 21 The FDA took this broad action even though it found no signs of contamination
whatsoever in a second batch of Chilean grapes. 22 Unsurprisingly, Chilean fruit suffered
economically in the American marketplace as a result of the scare generated from the
FDA's press release regarding possible contamination. 23
FDA press releases that mislead American consumers and the general marketplace
have dramatic and widespread effects. Unfortunately, broad, initial negative statements
about products attract more attention than subsequent corrections or retractions. In one
study, 160 newspapers reported negative information about a product - but only half
of those newspapers published a retraction. 24 Even when a statement is not an outright
press release from the FDA, statements from sources viewed by the general public
as associated with the FDA can still have negative consequences for those whom are
concerned with the subject material. 25 Even though the FDA does not intentionally create
this misunderstanding, it still causes great harm to the manufacturers and producers at
issue. 26 For example, in summer 2014, FDA branch chief Monica Metz claimed, in the
form of a constituent update posted on FDA's website, that the agency planned to ban
the traditional technique of aging artisan cheeses on wooden shelves, citing the risk of
bacteria growth. 27 It was not an official press release but still scared many American
cheesemakers and cheese lovers.

17

Id.

FederalTort Claims Act (FTCA), 28 US.C. § 2680 (2014) \b'~"''"" omviv'"" 1m1nUintyto the
government
"any claim based upon an act or omission of an
of the Government,
vAvivio•rns due care, in the execution of a statute or
based upon the exercise or
f":"1mmou11,,•c--...m the part of a federal agency or an
of the Government, whether or not the
discretion involved be abused.").
18

19

Willis supra note 8, at 5
that a press release can lead to
and decreased stock market value).

° Fisher Bros. Sales, Inc.

2

21

22

US., 46 F.3d 279, 282

Cir. 1995).

Id. at 287.
Id.

24

Inron~arwnDisclosure,

§ 25.01 (2015).
:hP.PSPmnkinP-.

26

suits, brand

FDA (June 11, 2014)

Id.
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Considering the FDA's influence, it must exercise greater caution before issuing
negative information about consumer products. If the FDA reasonably believes, but
has not confirmed, that a product will threaten American consumers' lives, it may
need to disseminate a warning immediately. In a situation like this, an immediate and
effective press release can be a great exception to the need for caution and careful steps.
Unfortunately, the FDA has not created any procedure for this kind of exceptional
situation, which would probably require consultation with outside experts and an
immediate recall of the product. 28 The FDA would benefit from such a procedure:
for example, it would have been extremely helpful in early 2014, when the FDA first
encountered a crisis centering on power morcellators. 29 This crisis has continued
for months and has even prompted the U.S. House of Representatives to call for an
investigation of the FDA's regulation of medical devices. 30
Another growing concern is that the FDA fails to perform the investigations and audits
that may help regulated entities to comply voluntarily and avoid adverse publicity. 31
In 2011, the FDA failed to perform its own audits of facilities associated with food
preparation in one-third of U.S. states; instead, it relied on state entities' inspections of
those facilities. 32 The FDA has also reduced its staff and conducted fewer food product
safety tests, even as manufacturers have initiated a greater number of food recalls, over
the past fifteen years. 33 Instead, the FDA has used broadly worded and inexpensive
press releases to compel manufacturers to voluntarily recall their products. 34 If the FDA
continues to use press releases to enforce its regulations, it must try to decrease the
chance of undue alarm and misinformation, and not harm companies that are in full
compliance with the FDCA.

28

Power Morcellator Activist Protests FDA Failure to Ban Uterine Morcellation, BERNSTEIN
LIEBHARD LLP (Nov. 11, 2014), http://WV1-w.pmewswire.com/news-releases/power-morcellatoractivist-protests- f da-failure-to-ban-uterine-morcellation-bernstein-liebhard-llp-reports-2813 23621.
html
Dr. Amy Reed, doctor and cancer
recall of the
power morcellator, a medical device
used in minimally invasive <11rapr·1,,< and furiously upset with the lack of action and several months
of time the FDA spent
recall of the medical device that possibly causes
uterine cancer).
29 Id.
30

Jennifer Levitz, House Passes Bill to Improve

J. (July 12, 2015) available at htt0n·//umJwmo1
monitoring-of-medical-devices-1436736213.
31

Vulnerabilities in FDA s
Inspections, HHS
(2011 ),
hhs.gov/oei/reports/oei-02-09-00430.pdf.
Id.

OFFICE OF INSPECTOR

GENERAL
32

33 David Morgan, Despite Food Scares, FDA Cuts Inspections, CBS (Feb. 26, 2007),
cbsnews.com/news/despite-food-scares- fda-cuts-inspections/.

34

nrnr1r"1'"·w

FDA Enforcement Statistics Summary Fiscal Year 2013, supra note 12.
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II. UNDERSTANDING THE OBSTACLE
A manufacturer unduly harmed by an inaccurate or overblown press release has little
recourse, largely because the FDA has broad discretion to act against potentially harmful
products. 35 Furthermore, the Federal Tort Claims Act (FTCA) generally protects federal
government entities from liability. 36 As a result, the FDA can only be found liable
for breaching its duty of care. 37 However, since Congress has declared that the FDA
alone has the expertise to ensure that foods, drugs, and medical devices are safe for
public use, courts are unlikely to second-guess the FDA's decisions. 38 This discretion
is reflected in the Administrative Procedures Act ("APA"), which directs courts to defer
to most decisions by the FDA and other administrative agencies. 39 Consequently, it
is quite unlikely that a court will find that the FDA erred when the agency issued a
precautionary press release. 40 Upon creating the FDA, Congress primarily intended to
do away with Sinclairian producers and manufacturers. 41 Congress simply assumed that
the FDA would exercise good reasoning while seeking to improve health and safety in
the American marketplace.
When adverse publicity results in a company's demise, it is difficult to build each
necessary part of the case against the FDA. First, a plaintiff must exhaust all available
agency remedies and fulfill other difficult requirements to overcome the FTCA's general
grant of sovereign immunity. 42 Even then, the plaintiff must demonstrate that the FDA's
negative press release caused its economic harm. 43 It will be difficult to establish that
the FDA's statements about a company's alleged violations of the FDCA proximately
caused consumers to abandon the company's products. It is possible that consumers
simply preferred competing products and the market worked as it should. Even if the
plaintiff can prove causation, the plaintiff must then prove its harms. These hurdles may
dissuade some plaintiffs for even seeking judicial redress.
35

28 U.S.C. § 2680 (2012) (granting discretion to the FDA and limiting judicial review of the
FDA's actions).
36 Id.
37

Mark Niles,
but
The Federal Tort Claims Act and the Scope
Immunity, 54 ADMIN. L. REv. 1275 (2002).
38

21 U.S.C. §

(2012).

39

Administrative Procedure Act, 5 U.S.C. § 706 (2012) (providing that judicial review is only
warranted when administrative agencies act contrary to, or in excess of, statutory or constitutional
authority).
40

See Lars Noah, Governance
the Backdoor: Administrative
at the FDA, 93
NEB. L. REV. 89, l 28 (2014) (suggesting that adverse publicity is a form ofa procedural short cut
that the FDA uses to avoid jmlicial proceedings).
41

See
UPTON SINCLAIR, THE JuNGLE (See Sharp Press 2003) (1906) (exposing hazardous
conditions and health code violations of workplaces within the meat-packing industry).

42

See 5 U.S.C. § 704 (outlining administrative exhaustion requirement).

43

Mizokami v. United States, 414 F.2d 1375, 1376-77, 1381 (Ct. Cl. 1969) (obtaining a private
bill from Congress to waive FDA's sovereign immunity and determining that "sufficient connection
had been proven between the [FDA] 's actions and the alleged losses"). In Mizokami, a private law
allowed plaintiff vegetable growers who claimed that their spinach crops were contaminated with
pc>ul01uc> to file suit
FDA. Id. at 1376-77. Along with waiving FDA's immunity, the bill also
for the actions and left it to the comt to decide damages for
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A negative press release has lasting effects on manufacturers and consumers. Adverse
publicity lingers even after the information is found to be untrue. 44 Unfortunately, the
FDA rarely issues corrections and retractions; when the FDA does, it receives much less
attention, and it might create even more confusion about whether the products are safe. 4s
Specifically, the FDA only revisits a negative statement after determining that everything
possible to improve or completely remove the product from the market has been done,
and after several FDA offices coordinate in writing with one another. 46 Therefore, it is
difficult for manufacturers to recover from adverse publicity.
A. Internet Pains and Not Enough Gains

The FDA's failings in issuing press releases, which potentially cause undue recalls
and consumer misinformation, are compounded by the nature of the World Wide Web.
Most unfortunately, the "Internet serves as a content multiplier, and when capital
markets seize information without verifying the details, the velocity and severity of the
fallout can be even greater." 47 The FDA and other government agencies particularly
struggle to communicate accurately over social media sites like Twitter, which call
for a brief statement and a link to a formal press release. The FDA's recent social
media campaign through the FDA Adverse Event Reporting System (FAERS) is a
perfect example. 48 This proposed system would search the Internet for adverse events
involving regulated products, which have not yet been reported to the FDA. 49 The
FDA's guidance document on the proposed system focuses on how food and drug
manufacturers should be properly labeling and marketing their products on social
media outlets.so It even discusses how to address Twitter's 140-character limit.SI The
system would empower consumers to report perceived violations of the FDCA directly

44

See Nathan Cortez, Adverse Publicity
in the Internet Era, 2011
BYU L. REv. 1371, 1403 (2011) (suggesting that the FDA often acts on "limited information and
scientific uncertainty").

45

See 21 C.FR § 7.55(a) (2015) (outlining the steps for terminating an FDA recall).

46

Id. A recall will be terminated when the Food and Drug Administration determines that all
reasonable efforts have been made to remove or correct the product in accordance with the recall
strategy, and when it is reasonable to assume that the product subject to the recall has been removed
and proper disposition or correction has been made commensurate with the degree of hazard of the
recalled product Written notification that a recall is terminated will be issued
the appropriate
Food and Drug Administration district office to the recalling firm
47

Cortez, supra note 44 at 1401.

Event Surveillance, FDA, http://V1;ww.fda.gov/
ScienceResearch/SpecialTopics/RegulatoryScience/ucm455305.htm
49 Id
48

on Social lvfedia and Internet
Communications About Medical Products: Designed with Patients in Mind, FDA VOICE BLOG (June
17, 2014 ), http:/iblogs.fda.gov/fdavoice/index.php/2014/06/fda-issues-draft-guidances-for-industryon-social-media-and-internet-communications-about-medical-products-designed-with-patients-inmind/.
51

Internet/Social Media Platforms with Character Space
limitations- Presenting Risk and
Prescription Drugs and
Medical Devices (Draft
FDA (2014), http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegnlatoryinformation/Guidances1UCM401087.pdf
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to the FDA. 52 However, many commentators, including physicians, were quite dubious
that the FDA would be able to process and analyze these reports. 53 It could simply be
seen as the FDA trying to keep up with the times.
In general, consumer panic about a particular product could prevent the manufacturer
from telling its side of the story and might lead to the collapse of that manufacturer or
the entire industry. As long as the internet remains an unfiltered and unregulated world
ofbloggers and news watchdogs, the FDA must attempt to issue accurate statements and
discourage the public from overreacting and furthering unfounded allegations. 54
The FDA's use of the internet has only intensified its ability to create adverse publicity.
There is a grave possibility that FDA statements will spread too quickly and become
distorted before manufacturers can properly respond. 55 Furthermore, the FDA is not
required to give advanced notice to manufacturers before issuing press releases. 56
Manufacturers may be caught entirely off-guard and may struggle to respond accurately
and effectively to the public and to government regulators.
The FDA's broad communication can reach consumers in numerous ways. In print alone,
agency publications like the FDA Consumer reach a circulation of more than 25,000
paid subscribers. 57 Furthermore, an individual may sign up for multiple FDA mailing
lists, which can add up to 4 emails a day. This high number of original communications
from the FDA can then become twisted and misconstrued on the internet as they are
removed and become indirect communications, in ways that even the most sensationalist
newspapers of the FDA's early days could not imagine because of the multiple levels
between the actual source and what the audiences consumes. 58 So when an initial
press release is inaccurate or incomplete, it is even more likely that the press release's
dissemination on the internet will create panic.
While the FDA cannot control everything that is said on the Internet or in the press, the
FDA should maintain better control, self-restraint, and due diligence in making sure
that its press releases are as factually sound and clear as possible. 59 Such control could
include consulting with experts outside of the agency when necessary and investigating
matters further before releasing negative press releases, especially when there are no
members of the FDA specialized and duly prepared to assess a particular product.

52
See Abrams, supra note 50
the consumer).

53

that the focus of the social media

is

for

Lena J. Weiner, FDA s Social 1\!edia Gambit 'A Long Shot,' Says Patient Advocate, HEALTH
(August 13, 2014 6:45 AM)

LEADERS MEDIA

See Cortez, supra note 44, at 1395 \ rn~;cu:ssn1g
social media).
56

Johnson, supra note 15, at 10.

57

Id. at 13.

58

Cortez, supra note 44, at 1371.

59

Id. at 1376.
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B. What the FDA World Needs Now
Consumers, manufacturers, and retailers alike deserve a better process through
which they can learn about truly dangerous or unsafe products. The FDA should only
communicate reliable, factual, and timely information about investigations of products
and manufacturers, including whether those investigations are pending or completed.
In addition, the FDA must consider the public's likely reaction before making any
announcement, to minimize the possibility of harm and maximize the potential of
protecting consumers. In other words, the FDA should inform consumers about
dangerous products, but should not push consumers to become hostile towards any
brand or industry. By striking this balance, the FDA can ensure consumer safety without
creating undue consumer panic.
III. THE PROBLEM AS FOUND IN TODAY'S HEADLINES
A. The Tragedy
The FDA demonstrated its ability to create chaos and confusion in its recent treatment of
the laparoscopic power morcellator (LPM). An LPM is used to perform hysterectomies
(surgical removal of the uterus) and myomectomy (surgical removal ofuterine fibroids). 60
FDA regulation of the LPM began, like its regulation of many products, with tragedy.
Specifically, the FDA took notice of Dr. Amy Reed's campaign to demonstrate how
a common procedure used to remove otherwise benign uterine fibroids from women
could actually lead to cancer. 61 Fibroids are common, benign uterine growths that can
be easily removed and most of the time are recommended to be removed, as the growths
could later become cancerous. 62 However, the LPM was found, in certain cases, to leave
behind portions of the fibroid within the woman's uterus and become malignant some
months, or sometimes sooner, after the procedure. 63 After this occurred to Dr. Reed, she
resolved to publicize the procedure's risks.
The LPM's use in myomectomies has been and continues to be praised by some. 64 In
April 2014, the FDA estimated that this surgery is performed at least 50,000 times in
the United States each year. 65 It is minimally invasive, requires very little recovery time,
and generally succeeds at removing uterine fibroids from a place where they would
be too small to develop samples to test for cancer prior to the fibroids removal. 66 The
LPM's spinning blade slices fibroid tissue into smaller pieces and removes those pieces

61

IT
62

Id. at 9-12.

63

FDA,

64

65

& JoN KAMP,
34, 53, 67

JENNIFER LEVlTZ

LEAVES BEHIND

LEVITZ

DEADLY MEDICINE:

A

COMMON SLJRGERY FOR WOMEN AND THE CANCER

St J. ed. 2014).

2014 Press Release, supra note 60.
&

KAMP,

note 61, at 49-50, 56.

Id at23.

66

at 9-10, 12-13.
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through small incisions. 67 This procedure may be performed with a bag to catch spare
pieces of the fibroids that can spread into the uterus. 68 Unless the gynecologist uses a
bag with the LPM, some of the fibroid fragments may spread and be left behind in the
uterus after surgery. 69 However, gynecologists routinely used the LPM device without
a bag in removing uterine fibroids. 70
Dr. Reed, an anesthesiologist and mother of six, is attempting to use her own experience
to push the FDA to regulate the LPM. She had the basic surgery to remove uterine
fibroid tumors using the LPM, but eight days later, she learned it had worsened her
prognosis by spreading cancer from the remaining uterine fibroids. 71 The shredding
of the fibroid inadvertently spread the undetected cancer because the fragments were
uncontained. 72 Throughout fall 2014, while Dr. Reed's cancer had progressed to stage
four, her husband focused on writing letters to the FDA, questioning its failure to act
about the potentially deadly medical device. 73 While many agree with Dr. Reed's calls
for action, others argue that the device is safe and that the FDA created a mountain out
ofa few exaggerated facts. 74
At the time of this writing, Dr. Reed had a recurrence of her cancer, a tumor in her
spine, but that has not stopped her avid fight for justice. 75 She is now involved in an
FBI investigation about whether the device's manufacturer, Johnson & Johnson, knew
about the risks as early as 2006. 76 Dr. Reed argues that she and other patients should
have been better protected and this story involves "a violation of federal law that has led
to the loss oflife."77

67

Jon Kamp, More Health Insurers Take Action to Curb Morcellator Use, WALL ST. l (Apr.
2, 2015), available at http://wwwwsj.com/articles/more-health-insurers-take-action-to-limitmorcellator-use-1428009386.
68

Id

69

LEVITZ &

70

Id. at 24-25.

71

Id. at 13-15.

KAMP,

supra note 61, at 24.

72

Doctor with Cancer Raises Alarm about lvledical Device, CBS NEWS (June 4, 2015),
cbsnews.com/news/doctor-with-cancer-morcellator-medical-device/.
73

BERNSTEIN

Lrnm!ARJJ LLP, supra note 28.

74

Jennifer Levitz & Jon Kamp,
Resist FDA
Tool, WALL ST. J
(Sept 21, 2014), available at http://,;vww wsj .com/articles/gynecologists-push-back-on-fdas-cautionabout-cancer-when-using-morcellation-in-hysterectomies-1411358341 (reporting that obstetrics and
gYJ1ecolo1g1sts alike were
over the use LPMS in
even after the FDA d1sc01lfaJ~ed
their use); see also Jon Kamp, J&J's
lvforcellator Sales Leaves
Others,
WALL ST. J (Sept 23, 2014 ), http://blogs.wsj.com/corporate-intelligence/2014/09/23/jjs-exit-frommorcellator-sales-leaves-opportunities-for-others/.
75
76
77

CBS NEws, supra note 72.
Id

Id; see also

BERNSTEIN

LIEBHARD LLP, supra note 28.
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B. The First Press Release
In April 2014, the FDA issued its first press release regarding the LPM. 7s However, the
press release simply asked doctors to reconsider the possibilities of harm posed by use
of the LPM: a less than useful recommendation. With separate statements of caution,
warning, and urging of doubt regarding the procedure's benefits and risks, the FDA's
press release revealed that the benefits of the device may be limited due to the potential
development after surgery, of uterine sarcoma, that had not been found or realized prior
to surgery. 79 The release itself was extremely limited and offered little research data or
clarity about the device's use in the future.so However, the press release did claim that
the LPM causes cancer in 1 in 350 women and further stated:
There is a risk that the procedure will spread the cancerous tissue within the
abdomen and pelvis, significantly worsening the patient's likelihood of longterm survival. For this reason, and because there is no reliable method for
predicting whether a woman with fibroids may have a uterine sarcoma, the FDA
discourages the use of laparoscopic power morcellation during hysterectomy
or myomectomy for uterine fibroids.s 1
The FDA admitted that this reasoning was based on only a survey of the small amount
of information on the dangers of the medical device available at the time. s2 While the
concern for the medical device had been slowly growing since approximately 2006,
available information and studies about the device had unfortunately not increased. In
the April 2014 press release, the FDA also promised that an advisory committee would
review the device's risks in more detail that July. s3 Unfortunately, that committee only
conducted a general review of nine studies (one of which was only in abstract form).s 4
For the next five months, the FDA did not take any further actions regarding this
potentially cancer-inducing surgical device. During the FDA's period of silence,
individual and institutional providers offered their opinions about whether the device
should remain on the market. ss Many also criticized the FDA for discouraging use of
the device but not actually recalling the device or offering any conclusive answers. s6
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C. The Reaction

Following the FDA advisory committee's July 2014 meeting on the LPM numerous
U.S. doctors and hospitals, citing years of mistrust of the LPM, asked the FDA to
announce a complete recall. 87 The leading LPM manufacturer, Johnson & Johnson,
announced that it would keep its version from the market until the FDA made a
conclusion about the LPM's safety. 88 BlueCross/BlueShield, Highmark, and other
health insurance providers quickly followed suit by discontinuing reimbursement for
procedures that used the LPM. 89
However, this was not a one-sided debate. Other patients, doctors, hospitals, and
manufacturers argued that the FDA was making a mountain out of a perfectly fine and
functional molehill. 90 Many wondered whether the FDA had overstepped its boundaries
by declaring that 1 in 350 women treated with the LPM would develop cancer, without
offering conclusive support for that statement. 91 Some doctors proposed that the FDA's
risk analysis was incorrect and that the actual risk of undetected sarcoma developing
after the surgery was more likely to be 1 in 300. 92 Some commentators suggested that
the FDA should have considered patients' ages, history of other cancers, and other traits
that might have affect the benefits and risks of using the LPM to remove fibroids. 93
While manufacturers and healthcare providers had varying opinions about the LPM, it
became clear that those opinions could have helped FDA earlier in the process.
D. The Second Press Release
On November 24, 2014, the FDA issued a second press release that further discouraged
use of the LPM to remove uterine fibroids. 94 The FDA then suggested that "immediately
in effect," LPM packaging should include two additional safety wamings. 95 First, the
packaging should display a "black box waming" 96 disclosing that the operation could
increase the risk of spreading cancer throughout the body and worsen the patient's
likelihood oflong-term survival. 97 Second, the packaging must list contraindications for
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use of the LPM. 98 Overall, the second FDA press release encouraged doctors to have
more discussion of the LPM's risks and benefits with their patients. 99 The FDA further
promised that it would continue monitoring adverse event reports and information as it
became available on the medical device to protect public health. 100 However, the FDA's
assurance could be viewed as insufficient given the delayed warning.
E. The Silver Lining

Before the FDA's advisory committee convened and issued its conclusions in its second
press release, other stakeholders - manufacturers, doctors, hospitals, and insurersconducted their own fruitful discussion. However, one group above all clearly benefited
from the FDA's final conclusion: women considering procedures using the LPM.
Following the FDA's second press release, those women and their providers better knew
what to consider before choosing to use the LPM. The FDA was most useful when
it organized and disclosed all of the stakeholders' competing arguments and helped
patients to make their own informed decisions.
The FDA's actions prompted each patient and her doctor to engage in a more sustained
dialogue about whether to use the LPM. The FDA has also prompted doctors to ask
patients to sign informed consent forms before undergoing procedures, to share videos
of the LPM's use with other doctors, and to keep asking whether the LPM surgery is the
best option for each patient. 101 So while the FDA took almost five months to issue its
much-needed second press release, the FDA did help to initiate conversations between
patients and doctors. Admittedly, during the delay, patients and other stakeholders may
have begun to rely on the FDA's inaction and may have concluded on their own that the
FDA would not issue a recall of LPMs. However, either way, the process was beneficial
because patients began reviewing their options and making more educated decisions.
Despite this eventual success, the FDA has been criticized for its handling of the
LPM device. For example, a majority of doctors surveyed by the Wall Street Journal
agreed that the FDA should update its methods of regulating medical devices such as
the LPM. 102 Other government agencies are reviewing the FDA's actions and trying
to ensure that this does not happen again. The FBI is currently considering the FDA's
ability to effectively regulate medical devices, specifically since it initially approved
the LPM, which clearly carries some risks. 103 The FBI is conducting a second, separate
investigation centering on the LPM itself. 104 While the FBI acknowledges that the FDA
made the right moves toward resolving the issue with the medical device by requiring
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new warning labels on the product, the FBI is still seeking to find what information
should have come to light before even the first FDA press release back in July 2014. 105
Finally, members of the U.S. House of Representatives, in response to the LPM crisis,
have proposed an amendment to the "21st Century Cures" Act that would require more
Congressional oversight on the FDA's methodologies in determining whether a device
is "generally recognized as safe" for use in the marketplace. 106

IV. RECOMMENDED SOLUTIONS
With some reforms, the FDA can better inform American consumers about medical
devices and other consumer products. The FDA should ensure that the information
in each press release is thorough and well-supported by sufficient facts. 107 The FDA
should offer a notice and comment period to experts and stakeholders or should resolve
all material questions before issuing a press release, whenever it is possible to do so. 108
The FDA should also consider the public's knowledge of a product and the potential
for confusion, before rushing to issue a press release. 109 The FDA must also become
more effective at retracting and correcting negative statements, to effectively inform
the public and minimize undue harm to manufacturers. 110 In addition to FDA reforms,
private actors harmed by adverse publicity should be able to seek compensation when
they are harmed by inappropriate FDA action. 111
The LPM crisis demonstrates that the FDA should also find some way to address
emergency situations involving products that are already on the market. The FDA should
establish a taskforce that will respond to tips received through the new FAERS system. 112
Finally, the FDA must amend and retract flawed statements more effectively. 113 This
solution to the abuse and misuse of the FDA's power of publicity could come in the form
of an adjustment to the Administrative Procedure Act (APA) or the FDCA itself, through
the possible creation of an amendment to the FDCA. No matter where this amendment
occurs, it should include a higher standard of proof and research behind each press
release, notice to companies and industries prior to release, proper termination of recalls
and the mandate of corrective press releases, increased overall self-restraint by the FDA,
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and the creation of a task force that can quickly respond when there is a legitimate threat
of seriously harmful products. 114
A. Better Research
If the FDA is required to be more thorough and careful when drafting a press release,
it will be less likely to cause harm. 115 Instead, the resulting press release will be more
reliable and beneficial to the public. 116 Also, by always making sure that there is some
level of outside, specialized expert opinion involved in a press release regarding
the specific product and its functions, adverse publicity will be less likely to have
misleading or incorrect information in it. 117 By mandating a minimum amount of time
and research on a product prior to the press release, this amendment could occur without
too much extra cost and time to the FDA. This higher standard could also decrease the
amount of allegations that the FDA included in their press releases and further dispel
the opportunity for misinformation as the information trickled through social media.
The FDA could ban allegations in press releases altogether. Alternatively, in cases of
more significant risk or substantial harm, when the FDA needs to issue press releases, it
should require expert opinions and caveat the release by indicating the case is currently
an allegation, or that it lacks complete information. 118

B. Due Notice

Furthermore, the FDA should be required to offer some warning to manufacturers
before suggesting publicly that the manufacturers have not complied with the FDCA.
Due notice could mean that the FDA was required to give a reasonable amount of time
for manufacturers and producers to be able to comment or even correct the issue that
FDA found with the product, much like the standard voluntary recalls of the FDA. 119
Such a notice and comment period would protect manufacturers from undue adverse
publicity. 120 It might allow manufacturers to voluntarily recall potentially harmful
products while maintaining public goodwill. Reasonable notice could even be limited to
when the pending press release contains significant risk to either public health or (and
possibly one leading to the other) significant economic risk to the manufacturer upon
disclosure of the press release. 121 More than likely, if the FDA were more susceptible to
tort liability, the agency might be more willing to provide reasonable notice.
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C. Proper Terminations & Corrective Statements

The FDA could also further the public health by becoming more willing and effective at
amending or correcting press releases. The FDA should pay attention to new information
and public response to its press releases, and respond when necessary. These back-end
fixes to adverse publicity would provide some aid to manufacturers injured by misleading
or misinformed press releases. 122 Corrective press releases would also considerably aid
confused American consumers. Such follow-up press releases could report the final
outcome of FDA investigations and summarize the underlying research and evidence. 123
Given that the internet is a large cause of confusion and misinterpretation, the FDA
could arguably try to oversee all internet commentary on FDA regulatory action. 124
Because the use of social media has become so prolific, the FDA should incorporate
social media into FAERS to monitor the public's reaction to press releases and to
seek out adverse events to address. 125 Through the FDA's acceptance of an additional
medium to communicate with the public, it could effectively decrease the amount of
misinterpretation of FDA press releases, especially those leading to adverse publicity.
Integrating social media with FAERS will allow the FDA to promptly offer a corrective
follow up press release to cease confusion through its FAERS operator. 126 Twitter's one
hundred and forty characters will be feared no more.
D. Self-Restraint and Addressing Emergency Situations

Considering that the FDA's ability to create adverse publicity for manufacturers greatly
predated the Internet, the FDA should exercise more self-restraint overall. 127 The FDA
is responsible for regulating a great number of products, many of which are potentially
harmful or misleading to the public. However, the FDA does not need to issue public
press releases about each one of those violations unless they are emergency situations.
By exercising some self-restraint, the FDA would demonstrate that it is truly dedicated
to public health and would also improve its relationships with manufacturers. 128 Selfrestraint by the FDA could also generate public support for a task force that will respond
quickly to those products already on the market that pose imminent, serious threats to
public health, but only when such a task force is completely necessary. With dedicated
time and effort to study whatever available research exists and offer a recall or other
advisement on the product as soon as trouble is found, such a task force would effectively
guide the FDA to fulfilling its public service duty.
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E. Emergency Taskforce
An emergency task force will be extremely helpful at quickly responding to products
like the LPM, which are already on the market and potentially harming the public. In

such cases, the FDA cannot take five months or more to reach a conclusion. 129 Adverse
publicity here is simply not enough, even if it may scare up conversation between
patients and their healthcare providers. Because the FDA is the leading regulator of
such products, it should also be the leader in the conversation as to how to approach
the products. 130 As Dr. Reed pointed out in the LPM case, if the FDA fails to offer
answers, it violates its duty to protect the public from potentially harmful and unsafe
products. 131 An emergency taskforce can aid in the FDA's protection of the public by
utilizing available information and conducting additional field research to determine
whether an immediate response for a recall is required.

V. APPLICATION OF THESE RECOMMENDATIONS TO THE
LPMCRISIS
In lieu of the second press release's resolution, the recommended amendments to FDA's
use of publicity can be applied to the LPM crisis. The recommendations offer more
effective and possibly less panic arousing public health communication methods to
an agency committed to protecting consumers through the regulation of food, drugs,
cosmetics, and medical devices.
A.Research
The FDA's first press release regarding the LPM did not offer any definitive conclusions,
but merely suggested the LPM posed a "risk" that could worsen patients' survival. 132
The harmful effects of LPM became more apparent after testimony surfaced in the
FDA committee meetings with the Obstetrics and Gynecology Devices Panel and the
subsequent FBI Investigation. 133
The FDA admitted that there was little research on whether the LPM caused the later
development ofuterine sarcomas. The FDA should have thought further, and recognized
that eight studies and one abstract were not conclusive enough to announce that 1 in
350 women relying on the LPM would later develop cancer. 134 Relying on a small
number of studies and issuing a press release about a substantial public health issue
may indicate that the lack of substantiation by the FDA caused the FDA to breach its
duty to the public, or at least that there was a great deal of information left unturned. 135
By increasing the minimum threshold requirement for research studies cited, the FDA
could have had the support of more doctors and hospitals to support its position and
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dissuade the use of the medical device. If the FDA utilized dissemination channels with
direct access to patients: doctors, hospitals, and manufacturers, consumers would have
been immediately informed and dissuaded against the use of the medical device.
B. Due Notice

Notice would be a more difficult concept to tackle here simply because the medical
device industry under the regulation of the FDA is quite unlike the other consumer
products regulated by the FDA in that the product is not available to the everyday
consumer. However, if the FDA had given notice to both the manufacturers of the
surgical medical device and the hospitals and doctors who used them, then there might
have been a greater consolidation of the opinions regarding the medical device and
furthermore, a better understanding of how to properly treat patients with or without it.
There currently exists too much lag time between when information is available about
when a device is unsafe and when the FDA issues a public determination that a device is
unsafe. 136 Had the FDA notified device manufacturers, doctors, and hospitals earlier that
it was committed to further researching ill health effects, there could have been a greater
collaboration amongst everyone instead of the blowback the FDA received after issuing
the press release. Although LPM was life-threatening, in a less dangerous context, both
notification of industry personnel and consultation with experts provide stronger basis
for the FDA to release adverse publicity. By collaborating its efforts, the FDA not only
decreases the hostility the industry feels toward the agency, but it also increases the
likelihood for voluntary participation in its device program effectiveness efforts.
C. Emergency Taskforce

The LPM is also a prime example of products already on the market potentially causing
harm, which the FDA should investigate quickly. The FDA should not have taken nearly
five months to report its advisory committee's findings in its second press release. The
delay justifies distrust of the FDA as it currently operates and questions about whether
the FDA is truly doing its best to protect the public welfare. If the FDA had an emergency
taskforce when this crisis arose, it could have acted more quickly.

CONCLUSION
While the FDA is tasked with protecting the health of consumers by regulating products
in the marketplace, its authority for use of publicity should be limited. 137 At the very
least, the FDA must exercise care and minimize unnecessary harm to manufacturers and
consumers. 138 This is particularly important as the FDA increasingly relies on adverse
publicity to warn the public ofpotentially harmful products and threaten manufacturers
to recall those products voluntarily. 139
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Adverse publicity often creates the burden of stress for consumers, especially when a
press release is later proven untrue or misrepresented. When consumers panic or fail to
adequately understand FDA warnings, manufacturers suffer economically. Therefore,
the FDA must gather adequate data and provide notice to manufacturers before issuing
a press release containing adverse publicity. The FDA should also exhibit self-restraint
on what to put into the media stream and be prepared to issue corrective statements
and retractions in the case of false or misleading information. Congress can mandate
these improvements by amending the FDCA or the APA, or the FDA can voluntarily
implement these improvements.
Combined, these changes would improve the FDA's ability to make public statements
that effectively protect consumers from dangerous products without unduly punishing
manufacturers with unreasoned adverse publicity. If the FDA conducts proper research
and utilizes its resources, the next time a product raises immediate concern, the FDA
will be able to expeditiously address the issue, keep consumers informed, and strengthen
its relationship with regulated entities.
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